Partnered Program B

About Immuneering

Immuneering is a clinical-stage biotech founded in 2008, focused on transforming cancer treatment by addressing the fundamental challenge of therapeutic resistance. Its core innovation is the Deep Cyclic Inhibitor platform, which administers potent drugs in rapid pulses designed to disrupt tumor adaptation faster than it can occur, while sparing healthy tissue. The company is advancing a pipeline of novel and partnered programs targeting the ubiquitous MAPK pathway, with its lead candidate, IMM-1-104, in Phase 1/2a development for advanced solid tumors. Immuneering's strategy aims to deliver more durable tumor control with improved tolerability, potentially resetting the standard of care in oncology.

Therapeutic Areas

Other Undisclosed oncology target Drugs